Antistatic spacer with inhaler improved asthma control and reduced ED visits, study found
A study has found that using an antistatic spacer with an inhaler gave patients better asthma control.
A study has found that using an antistatic spacer (AC+FV AVHC) with an inhaler gave patients better asthma control, resulting in 13% less emergency department (ED) visits, and reducing hospitalisations by up to 19%.
The study looked at patients with asthma who could be followed up for at least 12 months. The patients were split into two groups. One cohort of patients used the AC+FV AVHC (9,325 patients) with an inhaler and the other group (9,325 patients) used non-antistatic spacers with inhalers.
The study analysed the evidence by assessing the delayed time a patient visited an ED (not leading to a hospital admission) with an asthma diagnosis; or an oral corticosteroids prescription fill within 30 days of a physician visit with an asthma diagnosis; a severe account was when there was an inpatient admission claim with an asthma diagnosis.
All patients had to be treated with long-term controller medication or fixed-dose combination of inhaled corticosteroids and long-acting b2 agonist (ICS/LABA) metered dose inhalers within 60 days before, or 60 days after, the index date on the spacer.
The study found that using the AC+FV AVHC resulted in fewer ED visits and lower exacerbation-related costs when compared with control non-antistatic spacers. The implication is that an antistatic spacer, in conjunction with an inhaler, may result in better asthma control.
Burudpakdee C, Kushnarev V, Coppolo D et al (2017) A Retrospective Study of the Effectiveness of the AeroChamber Plus Flow-Vu Antistatic Valved Holding Chamber for Asthma Control. Pulmonary Therapy. doi: 10.1007/s41030-017-0047-1